Details for New Drug Application (NDA): 202799
✉ Email this page to a colleague
NDA 202799 describes OMONTYS PRESERVATIVE FREE, which is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are two patents protecting this drug. Additional details are available on the OMONTYS PRESERVATIVE FREE profile page.
The generic ingredient in OMONTYS PRESERVATIVE FREE is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.
The generic ingredient in OMONTYS PRESERVATIVE FREE is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.
Summary for 202799
| Tradename: | OMONTYS PRESERVATIVE FREE |
| Applicant: | Takeda Pharms Usa |
| Ingredient: | peginesatide acetate |
| Patents: | 2 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 202799
Generic Entry Date for 202799*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;INTRAVENOUS, SUBCUTANEOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | Strength | EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML) | ||||
| Approval Date: | Mar 27, 2012 | TE: | RLD: | No | |||||
| Patent: | 7,550,433 | Patent Expiration: | Jun 2, 2026 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE | ||||||||
| Patent: | 7,919,461 | Patent Expiration: | Jun 2, 2026 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE | ||||||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | Strength | EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML) | ||||
| Approval Date: | Mar 27, 2012 | TE: | RLD: | No | |||||
| Patent: | 7,550,433 | Patent Expiration: | Jun 2, 2026 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE | ||||||||
Expired US Patents for NDA 202799
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa | OMONTYS PRESERVATIVE FREE | peginesatide acetate | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 202799-004 | Mar 27, 2012 | 7,919,118 | ⤷ Get Started Free |
| Takeda Pharms Usa | OMONTYS PRESERVATIVE FREE | peginesatide acetate | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 202799-005 | Mar 27, 2012 | 7,414,105 | ⤷ Get Started Free |
| Takeda Pharms Usa | OMONTYS | peginesatide acetate | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 202799-008 | Mar 27, 2012 | 7,414,105 | ⤷ Get Started Free |
| Takeda Pharms Usa | OMONTYS PRESERVATIVE FREE | peginesatide acetate | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 202799-001 | Mar 27, 2012 | 7,084,245 | ⤷ Get Started Free |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
